Publisher combats ad spend drought

Share this article:
Elsevier is rolling out a series of electronic newsletters and ramping up patient guides and other direct-to-patient (DTP) offerings as it struggles to cope with a drop off in journal ad spend.
The medical publishing titan expects to see a 5-7% drop in spending on journal ads this year, as pharma firms pull resources out of traditional professional advertising and detailing and plow it back into online activity and consumer promotion.

Elsevier sees opportunity in shrinking sales forces.

“Our strength is in the physician, and we want to capitalize on that,” said Luis Portero, VP commercial sales for Elsevier's journals group.

Portero sees spending on online advertising to physicians and DTP promotion via the doctor replacing some of that which went into detailing—a channel that, he notes, was growing by double digits until recently. To that end, the publisher recently produced patient guides for Unilever's Vaseline which were bundled with copies of The American Journal of Medicine—in turn, sporting a sponsored cover to complement the patient guides.

Elsevier is also launching a series of online newsletters over the next six months—across its pediatrics, OB/GYN and urology titles—patterned on the pilot of AJMPlus, an e-mail recap of The American Journal of Medicine that goes out to 30,000 physicians weekly. AJMPlus directs readers to the journal's Web site, which is linked to those of other Elsevier journals, allowing subscribers to search across multiple titles—and allowing advertisers to buy across numerous journals.

Portero sees online spend increasing as younger, “Web native” physicians—those in their 30s and younger—increase in number. “The younger generation learns differently,” says Portero. “Paper is not going to go away, but online is going to be more of a preferred venue.”

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...